APRE | Aprea Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.07 - 3.26
52 Week Range	2.9900 - 8.85
Beta	1.41
Implied Volatility	506.85%
IV Rank	100.00%
Day's Volume	5,779
Average Volume	9,356
Shares Outstanding	5,431,900
Market Cap	16,757,412
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-10-03

Valuation
Profitability
Growth
Health
P/E Ratio	-1.02
Forward P/E Ratio	N/A
EPS	-3.01
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	7
Country	USA
Website	APRE

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

APRE's peers: SILO, PTIXW, RZLT, LUMO, ANEB, ZIVO, RNXT, TPST, IKNA, CBIO, ERYP, APM, SRZN, UNCY, ARMP, ADAG, ACRV, ANAB, MLYS, GBIO, FBRX, MGTA, TCON, LOGC

*Chart delayed

Analyzing fundamentals for APRE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see APRE Fundamentals page.

Watching at APRE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on APRE Technicals page.